U.S. President Joe Biden on Tuesday (April 13) sought to allay concerns that the pause in inoculations of the Johnson & Johnson vaccine for COVID-19 would not negatively impact the ability of Americans to be vaccinated.
“There is enough vaccine that is–, basically a hundred percent unquestionable for every single, solitary American,” Biden said at the White House.
The president suggested that neither the Pfizer vaccine nor the Moderna vaccine had the same trouble as the Johnson & Johnson vaccine and there was as much as 600 million doses of those two vaccine types available.
U.S. federal health agencies recommended pausing the use of Johnson & Johnson’s COVID-19 vaccine for at least a few days after six women under age 50 developed rare blood clots after receiving the shot, dealing a fresh setback to efforts to tackle the pandemic.
Johnson & Johnson (J&J) said it would delay rollout of the vaccine to Europe, a week after regulators there said they were reviewing rare blood clots in four recipients of the shot in the United States.
Acting U.S. Food and Drug Administration Commissioner Janet Woodcock said the agency expected the pause to be a matter of days, and was aimed at providing information to healthcare providers on how to diagnose and treat the clots.
The moves come after European regulators said earlier this month they had found a possible link between AstraZeneca’s COVID-19 vaccine and a similar rare blood clotting problem that led to a small number of deaths.
(Production: George Tamerlani)